handroanthus_impetiginosus_mart._ex_dc._mattos
Unterschiede
Hier werden die Unterschiede zwischen zwei Versionen angezeigt.
Nächste Überarbeitung | Vorhergehende Überarbeitung | ||
handroanthus_impetiginosus_mart._ex_dc._mattos [2014/10/10 10:55] – angelegt andreas | handroanthus_impetiginosus_mart._ex_dc._mattos [2015/06/13 09:38] (aktuell) – Externe Bearbeitung 127.0.0.1 | ||
---|---|---|---|
Zeile 1: | Zeile 1: | ||
- | Handroanthus impetiginosus (Mart. ex DC.) Mattos - syn.Tabebuia impetiginosa (Mart. ex DC.) Standl. - Bignoniaceae \\ | + | Handroanthus impetiginosus (Mart. ex DC.) Mattos - syn.Tabebuia impetiginosa (Mart. ex DC.) Standl., Tabebuia ipe Mart., Tabebuia avellanedae Lorentz ex Griseb., Tabebuia heptaphylla Vell. - Bignoniaceae \\ |
- | pink lapacho, red lapacho, **Lapacho** | + | pau d' |
- | Deciduous tree, up to 30m high, native to Central and South America. | + | Deciduous tree, up to 20m high, native to Central and South America; bark light grey, inside reddish-brown; |
- | + | ||
- | "Red Lapacho (Tabebuia impetiginosa, syn. Tabebuia avellanedae), a canopy tree indigenous to the Amazonian rainforest and other parts of South America, | + | |
- | + | ||
- | As early as 1873, biomedical uses of Red Lapacho | + | |
- | + | ||
- | Two main bioactive components have been isolated from Tabebuia impetiginosa: | + | |
- | + | ||
- | The drug appears to be generally safe and one of the most important interactions of Tabebuia impetiginosa has been associated | + | |
- | + | ||
- | The botanical (drug) material available on the international markets seems to be of varying quality and composition, | + | |
+ | "Red Lapacho (Tabebuia impetiginosa, | ||
+ | As early as 1873, biomedical uses of Red Lapacho (“Pau D’Arco”) were reported. In 1967 after reports in the Brazilian press it came back to the light of clinicians (and the public in general). The news magazine O’Cruzeiro started reporting “miraculous” cures in cancer patients in a hospital. Natural sciences interest in the plant also began in the 1960s when the United States National Cancer Institute (NCI) systematically began researching plant extracts all over the world looking for active compounds against cancer and looked at Tabebuia impetiginosa in considerable detail. \\ | ||
+ | Two main bioactive components have been isolated from Tabebuia impetiginosa: | ||
+ | The drug appears to be generally safe and one of the most important interactions of Tabebuia impetiginosa has been associated with interference in the biological cycle of Vitamin K in the body. \\ | ||
+ | The botanical (drug) material available on the international markets seems to be of varying quality and composition, | ||
The bioscientific evidence for products derived from Tabebuia impetiginosa is insufficient and one of the core challenges of future research will be – based on the recognition of the drug's widespread use – to establish appropriate quality control procedures. Further research into the clinical effects and the pharmacology of chemically characterized extracts is also warranted." | The bioscientific evidence for products derived from Tabebuia impetiginosa is insufficient and one of the core challenges of future research will be – based on the recognition of the drug's widespread use – to establish appropriate quality control procedures. Further research into the clinical effects and the pharmacology of chemically characterized extracts is also warranted." | ||
[Red Lapacho (//Tabebuia impetiginosa// | [Red Lapacho (//Tabebuia impetiginosa// | ||
+ | |||
+ | {{http:// |
handroanthus_impetiginosus_mart._ex_dc._mattos.1412938516.txt.gz · Zuletzt geändert: 2014/10/10 10:55 von andreas